Sign up Australia
Proactive Investors - Run By Investors For Investors

SeeThruEquity says Pressure BioSciences on pace to match 2015 guidance

SeeThruEquity CEO is pleased to see Pressure BioSciences exceed its top line guidance for the third quarter.
SeeThruEquity says Pressure BioSciences on pace to match 2015 guidance
The numbers add up for Pressure BioSciences.
SeeThruEquity reckons Pressure BioSciences (OTCQB:PBIO) looks on pace to match its 2015 annual estimate of $1.9mln in revenue, with growth in products and services augmented by a return of grant revenues.
 
The independent equity research firm issued an update on Pressure,  which provides technology for the preparation stage of lab testing in life science research, following recent results.
 
"We were pleased to see PBIO not only meet, but exceed its top line guidance for 3Q15," Ajay Tandon, chief executive of SeeThruEquity, said.
 
At the end of last quarter, management stated that the company should generate at least $500,000 in 3Q15 due to growing products and services revenue and in light of recent shipments and customer order activity, said SeeThruEquity.
 
Third-quarter top line results came in above $500,000, with revenues of $580,334 up 55.8% annually, a record for the company.
 
"This has been the trend for PBIO recently. At the beginning of the year, we noted that PBIO management guided for 2015 to be a watershed year for the company in which revenues would begin to achieve critical mass due to growth both from new products and services as well as grants.
 
Specifically, PBIO looks on pace to match our estimate of $1.9mln in revenue, with growth in products and services augmented by a return of grant revenues."
Based on the results and expectations for the near future, SeeThruEquity is maintaining its price target of $1.57 per share.
 
Shares of the South Easton, Massachusetts-based company rose 10.6% to $0.26 at 12:27 p.m. in New York.
View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

1528305384_Untitled-design-(3).jpg
June 07 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
cells
July 31 2018
Life science generally is developing at an incredible speed, says Joe Anderson

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use